Monoamine oxidase inhibitors: Perspective design for the treatment of depression and neurological disorders

Current Enzyme Inhibition

Volumn 12, Issue 2, 2016, Pages 115-122

  Mathew, Bijo ^a   Mathew, Githa E ^b   Suresh, Jerad ^c   Ucar, Gülberk ^d   Sasidharan, Rani ^e   Anbazhagan, Sockalingam ^f   Vilapurathu, Jobin K ^b   Jayaprakash, Venkatesan ^g  

^a Department of Pharmaceutical Chemistry   (India)

^b Grace College of Pharmacy   (India)

^c MADRAS MEDICAL COLLEGE   (India)

^d HACETTEPE UNIVERSITY   (Turkey)

^e Govt TD Medical College   (India)

^f Surya School of Pharmacy   (India)

^g BIRLA INSTITUTE OF TECHNOLOGY   (India)

Author keywords

Cheese effect; Depression; Docking; MAO A; MAO B; Parkinson s disease

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; BEFLOXATONE; BENZYLHYDRAZINE; BROFAROMINE; CLORGYLINE; DOPAMINE; HARMINE; ISATIN; LAZABEMIDE; METHYLENE BLUE; MOCLOBEMIDE; MOFEGILINE; MONOAMINE OXIDASE INHIBITOR; PARGYLINE; PIRLINDOLE; RASAGILINE; SAFINAMIDE; SELEGILINE; TOLOXATONE; TRANYLCYPROMINE; TYRAMINE; UNCLASSIFIED DRUG; ZONISAMIDE;

ALZHEIMER DISEASE; ANTIDEPRESSANT ACTIVITY; ARTICLE; CLINICAL TRIAL (TOPIC); DEPRESSION; DRUG DESIGN; DRUG SAFETY; DRUG TARGETING; ELECTRON TRANSPORT; ENZYME MECHANISM; ENZYME STRUCTURE; HUMAN; MOLECULAR DOCKING; MOLECULAR MODEL; NEUROLOGIC DISEASE; PANIC; PARKINSON DISEASE; PHASE 3 CLINICAL TRIAL (TOPIC); SOCIAL PHOBIA;

EID: 84981742462     PISSN: 15734080     EISSN: 18756662     Source Type: Journal    
DOI: 10.2174/1573408012666160402001715     Document Type: Article

References (78)

1. Walker, W.H.; Kearney, E.B.; Seng, R.L.; Singer, T.P. The covalently-bound flavin of hepatic monoamine oxidase. 2. Identification and properties of cysteinyl riboflavin. Eur. J. Biochem., 1971, 24, 328-331.
2. Shih, J.C.; Chen, K.; Ridd, M.J. Monoamine oxidase: from genes to behavior. Annu. Rev. Neurosci., 1999, 22, 197-217.
3. Singer, T.P. Perspectives in MAO: past, present and future. A review. J. Neural Transm. Suppl., 1987, 23, 1-23.
4. Gottowik, J.; Malherbe, P.; Lang, G.; Da Prada, M.; Cesura, A.M. Structure/function relationships of mitochondrial monoamine oxidase A and B chimeric forms. Eur. J. Biochem., 1995, 230, 934-942.
5. Saura, J.; Kettler, R.; Da Prada, M.; Richards, J.G. Quantitative enzyme radioautography with 3H-Ro 41-1049 and 3H-Ro 19-6327 in vitro: localization and abundance of MAO-A and MAO-B in rat CNS, peripheral organs, and human brain. J. Neurosci., 1999, 12, 1977-1999.
6. Yelekci, K.; Buyukturk, B.; Kayrak, N. In silico identification of novel and selective monoamine oxidase B inhibitors. J. Neural. Transm., 2013, 120, 853-858.
7. Holtzheimer, P.E.; Nemeroff, C.B. Advances in the treatment of depression. Neuro Therapeutics, 2006, 3, 42-56.
8. Zeller, E.A.; Barsky, J.; Berman, E.R. Amine oxidases. XI. Inhibition of monoamine oxidase by 1-isonicotinyl-2-isopropylhydrazine. J. Biol. Chem., 1955, 214, 267-274.
9. Davison, A.N. The mechanism of the irreversible inhibition of rat liver monoamine oxidase by iproniazid (marsilid). Biochem. J., 1957, 67, 316-322.
10. Yu, P.H.; Tipton, K.F. Deuterium-isotope effect of phenelzine on the inhibition of rat-liver mitochondrial monoamine-oxidase activity. Biochem. Pharmacol., 1989, 38, 4245-4251.
11. Schwartz, M.A. Monoamine oxidase inhibition by isocarboxazid. J. Pharmacol. Exp. Ther., 1962, 135, 1-6.
12. Fowler, C.J.; Mantle, T.J.; Tipton, K.F. The nature of the inhibition of rat-liver Monoamine-Oxidase Type-A and Type-B by the acetylenic inhibitors clorgyline, L-deprenyl and pargyline. Biochem. Pharmacol., 1982, 31, 3555-3561.
13. Silverman R.B.; Hiebert, C.K. Inactivation of monoamine oxidase-A by the monoamine oxidase-B inactivators 1-phenylcyclopropylamine, 1-benzylcyclopropylamine, and N-cyclopropyl-alphamethylbenzylamine. Biochemistry, 1988, 27, 8448-8453.
14. Finberg, J.P.M.; Gillman, K. Selective inhibitors of monoamine oxidase type B and the "cheese effect". Intl. Rev. Neurobiol., 2011, 100, 169-190.
15. Carradori, S.; Silvestri, R. New frontiers in selective human MAO.B inhibitors. J. Med. Chem., 2015, 58, 6717-6732.
16. Edmondson, D.E.; Binda, C.; Wang, J.; Upadhyay, A.K.; Mattevi, A. Molecular and mechanistic properties of the membrane-bound mitochondrial monoamine oxidases. Biochemistry, 2009, 48, 4220-4230.
17. Binda, C.; Milczek, E.M.; Bonivento, D.; Wang, J.; Mattevi, A.; Edmondson, D.E. Lights and shadows on monoamine oxidase inhibition in neuroprotective pharmacological therapies. Curr. Top. Med. Chem., 2011, 11, 2788-2796.
18. Zapata-Torres, G.; Fierro, A.; Barriga-González, G.; Salgado, J.C.; Celis-Barros, C. Revealing monoamine oxidase b catalytic mechanisms by means of the quantum chemical cluster approach. J. Chem. Inf. Model., 2015, 55, 1349-1436.
19. Zenn, R.K.; Abad, E.; Kastner, J. Influence of the environment on the oxidative deamination of p-substituted benzylamines in monoamine oxidase J. Phys. Chem. B., 2015, 119, 3678-3686.
20. Silverman, R.B.; Lu, X. Evidence against a nucleophilic mechanism for monoamine oxidase-catalyzed amine oxidation. J. Am. Chem. SOC., 1994, 116, 4129-4130.
21. Miller, J. R.; Edmondson, D. E. Structure-activity relationships in the oxidation of para-substituted benzylamine analogues by recombinant human liver monoamine oxidase A. Biochemistry, 1999, 38, 13670-13683.
22. Erdem, S. S.; Karahan, O.; Yıldız, I; Yelekci, K. A computational study on the amine-oxidation mechanism of monoamine oxidase: Insight into the polar nucleophilic mechanism. Org. Biomol. Chem., 2006, 4, 646-658.
23. Orru, R.; Adelco, M.; Edmondson, D. E. Do MAO-A and MAO-B utilize the same mechanism for the c-h bond cleavage step in catalysis? Evidence suggesting differing mechanism. J. Neural. Transm., 2013, 120, 847-851.
24. Abad, E.; Zenn, R.K.; Kästner, J. Reaction mechanism of monoamine oxidase from QM/MM calculations. J. Phys. Chem. B, 2013, 117, 14238-14246.
25. Kim, J. M.; Bogdan, M.A.; Mariano, P. S. Mechanistic analysis of the 3-methyllumiflavin-promoted oxidative deamination of benzylamine. A potential model for monoamine oxidase catalysis. J. Am. Chem. SOC. 1993, 115, 10591-10595.
26. Silverman, R.B. Radical ideas about monoamine oxidase. Acc. Chem. Res., 1995, 28, 335-342.
27. Edmondson, D.E.; Binda, C.; Mattevi, A. Structural insights into the mechanism of amine oxidation by monoamine oxidases A and B. Arch. Biochem. Biophys., 2007, 464, 269-276.
28. Fitzpatrick, P.F. Oxidation of Amines by Flavoproteins. Arch. Biochem. Biophys., 2010, 493, 13-25.
29. Vianello, R.; Repi_, M.; Mavri, J. How are biogenic amines metabolized by monoamine oxidases? Eur. J. Org. Chem., 2012, 36, 7057-7065.
30. Ramsay, R. Monoamine oxidases: The biochemistry of the proteins as targets in medicinal chemistry and drug discovery. Curr. Top. Med. Chem., 2012, 12, 2189-2209.
31. Tipton, K.F.; Singer, T.P. The radiochemical assay for monoamineoxidase activity-problems and pitfalls. Biochem. Pharmacol. 1993, 46, 1311-1316.
32. Tan, A.K.; Ramsay, R.R. Substrate-specific enhancement of the oxidative half-reaction of monoamine-oxidase. Biochemistry, 1993, 32, 2137-43.
33. Binda, C.; Newton-Vinson, P.; Hubalek, F.; Edmondson, D.E.; Mattevi, A. Structure of human monoamine oxidase B, a drug target for the treatment of neurological disorders. Nat. Struct. Biol., 2002, 9, 22-26.
34. Ma, J.C.; Yoshimura, M.; Yamashita, E; Nakagawa, A.; Ito, A.; Tsukihara, T. Structure of rat monoamine oxidase A and its specific recognitions for substrates and inhibitors. J. Mo.l Biol., 2004, 338, 103-114.
35. De Colibus, L.; Li, M.; Binda, C.; Lustig, A.; Edmondson, D.E.; Mattevi, A. Three-dimensional structure of human monoamine oxidase A (MAO A): Relation to the structures of rat MAO A and human MAO B. Proc. Nat. Acad. Sci. USA, 2005, 102, 12684-12689.
36. Binda, C.; Li, M.; Hubalek, F.; Restelli, N.; Edmondson, D.E.; Mattevi, A. Insights into the mode of inhibition of human mitochondrial monoamine oxidase B from high-resolution crystal structures. Proc. Natl. Acad. Sci. USA, 2003, 100, 9750-9755.
37. Son, S.Y.; Ma, A.; Kondou, Y.; Yoshimura, M.; Yamashita, E.; Tsukihara, T. Structure of human monoamine oxidase A at 2.2-angstrom resolution: The control of opening the entry for substrates/ inhibitors. Proc. Nat. Acad. Sci. USA., 2008, 105, 5739-5744.
38. Milczek, E.M.; Bonivento, D.; Binda, C.; Mattevi, A.; McDonald, I.A.; Edmondson, D.E. Structural and mechanistic studies of mofegiline inhibition of human recombinant monoamine oxidase B. J. Med. Chem., 2008, 51, 8019-8026.
39. Binda, C.; Wang, J.; Pisani, L.; Caccia, C.; Carotti, A.; Salvati, P.; Edmondson, D.E.; Mattevi, A. Structures of human monoamine oxidase b complexes with selective noncovalent inhibitors: safinamide and coumarin analogs. J. Med. Chem., 2007, 50, 5852-5858.
40. Binda, C.; Wang, J.; Li, M.; Hubalek, F.; Mattevi, A.; Edmondson, D.E. Structural and mechanistic studies of arylalkylhydrazine inhibition of human monoamine oxidases A and B. Biochemistry, 2008, 47, 5616-5625.
41. Binda, C.; Hubalek, F.; Li, M.; Castagnoli, N.; Edmondson, D.E.; Mattevi, A. Structure of the human mitochondrial monoamine oxidase B-New chemical implications for neuroprotectant drug design. Neurology, 2006, 67, S5-S7.
42. Ramsay, R. Inhibitor design for Monoamine oxidases. Curr. Pharm. Des., 2013, 19, 2529-2539.
43. Petzer, J.P.; Petzer, A. Caffeine as a lead compound for the design of therapeutic agents for the treatment of Parkinson’s disease. Curr. Med. Chem., 2015, 22, 975-988.
44. Mathew, B.; Mathew, G.E.; Uçar, G.; Baysal, I.; Suresh, J.; Vilapurathu, J.K.; Prakasan, A.; Suresh, J.K.; Thomas, A. Development of fluorinated methoxylated chalcones as selective monoamine oxidase-B inhibitors: Synthesis, biochemistry and molecular docking studies. Bioorg. Chem., 2015, 6, 22-29.
45. Mathew, B.; Uçar, G.; Yabanoğlu-Çiftçi, S.; Baysal, I.; Suresh, J.; Mathew, G.E.; Vilapurathu, J.K.; Nadeena, A.M.; Nabeela, P.; Lakshmi, V.; Haridas, A.; Fathima, F. Development of fluorinated thienylchalcones as Monoamine oxidase-B inhibitors: Design, synthesis, biological evaluation and molecular docking studies. Lett. Org. Chem., 2015, 12, 605-613.
46. Ferino, G.; Vilar, S.; Matos, M.J.; Uriarte, E.; Cadoni, E. Monoamine oxidase inhibitors: Ten years of docking studies. Curr. Top. Med. Chem., 2012, 12, 2145-2162.
47. de Beer, S.B.; Vermeulen, N.P.; Oostenbrink, C. The role of water molecules in computational drug design. Curr. Top. Med. Chem., 2010, 10, 55-66.
48. Mancera, R.L. Molecular modeling of hydration in drug design. Curr. Opin. Drug Devel. 2007, 10, 275-280.
49. Villacanas, O.; Madurga, S.; Giralt, E.; Belda, I. Explicit treatment of water molecules in protein-ligand docking. Curr. Comp. Aided Drug Des., 2009, 5, 145-154.
50. Delay, J.; Laine, B.; Buisson, J.F. The action of isonicotinylhydrazide used in the treatment of depressive states. Ann. Med. Psychol., 1952, 110, 689-692.
51. Zeller, E.A.; Barsky, J. In vivo inhibition of liver and brain monoamine oxidase by 1-Isonicotinyl-2-isopropyl hydrazine. Proc. Soc. Exp. Biol. Med., 1952, 81, 459-461.
52. Burger, A.; Yost, W.L. Arylcycloalkylamines. I. 2-Phenylcyclopropylamine. J. Am. Chem. Soc. 1948, 70, 2198-2201.
53. Tedeschi, R.E.; Tedeschi, D.H.; Ames, P.L.; Cook, L.; Mattis, P.A.; Fellows, E.J. Some pharmacological observations on tranylcypromine (SKF trans-385), a potent inhibitor of monoamine oxidase. Proc. Soc. Exp. Biol. Med., 1959, 102, 380-381.
54. Youdim, M.B.; Edmondson, D.; Tipton, K.F. The therapeutic potential of monoamine oxidase inhibitors. Nat. Rev. Neurosci., 2006, 7, 295-309.
55. Schwartz, T.L. A neuroscientific update on monoamine oxidase and its inhibitors. CNS Spectr., 2013, 18(Suppl 1), 25-32.
56. Lum, C.T.; Stahl, S.M. Opportunities for reversible inhibitors of monoamine oxidase-A (RIMAs) in the treatment of depression. CNS Spectr., 2012, 17, 107-120.
57. Da Prada, M.; Zurcher, G.; Wuthrich, I.; Haefely, W.E. On tyramine, food, beverages and the reversible MAOinhibitor moclobemide. J. Neural. Transm. Suppl., 1988, 26, 31-56.
58. Brown, C.; Taniguchi, G.; Yip, K. The monoamine oxidase inhibitor-tyramine interaction. J. Clin. Pharmacol., 1989, 29, 529-532.
59. Lotufo-Neto, F.; Trivedi, M.; Thase, M.E. Meta-analysis of the reversible inhibitors of monoamine oxidase type A moclobemide and brofaromine for the treatment of depression. Neuropsychopharmacology, 1999, 20, 226-247.
60. Ramsay, R.R.; Dunford, C.; Gillman, P.K. Methylene blue and serotonin toxicity: inhibition of monoamine oxidase A (MAO A) confirms a theoretical prediction. Br. J. Pharmacol., 2007, 152, 946-951.
61. Versiani, M.; Nardi, A.E.; Mundim, F.D.; Alves, A.B.; Liebowitz, M.R.; Amrein, R. Pharmacotherapy of social phobia: A Controlled study with moclobemide and phenelzine. Br. J. Psychiatr., 1992, 161, 555-556.
62. Sheehan, D.V. Current concepts in the treatment of panic disorder. J. Clin. Psychiatr., 1999, 60 Suppl-18, 16-21.
63. Ban, T.A. Pharmacotherapy of depression: a historical analysis. J. Neural Transm., 2001, 108, 707-716.
64. Bortolato, M.; Chen, K.; Shih, J.C. Monoamine oxidase inactivation from pathophysiology to therapeutics. Adv. Drug Deliv. Rev., 2008, 60, 1527-1533.
65. Yanez, M.; Padin, J.F.; Arranz-Tagarro, J.A.; Camina, M.; Laguna, R. History and therapeutic use of MAO-A inhibitors: A historical perspective of MAO-A inhibitors as antidepressant drug. Curr. Top. Med. Chem., 2012, 12, 2275-2282.
66. Drukarch, B.; van Muiswinkel, F.L. Drug treatment of Parkinson’s disease. Biochem. Pharmacol., 2000, 59, 1023-1031.
67. Wu, R.M.; Murphy, D.L.; Chiueh, C.C. Selegiline (l-deprenyl) as a unique neuroprotective agent for chronic neurodegenerative disorders-A lesson from MAO inhibition. Curr. Med. Chem. Centr. Nerv. Sys. Agents, 2004, 4, 255-267.
68. Petzer, A.; Grobler, P.; Bergh, J.J.; Petzer, J.P. Inhibition of monoamine oxidase by selected phenylalkylcaffeine analogues. J. Pharm. Pharmacol., 2014, 64, 677-687.
69. Youdim, M.B.; Bakhle, Y.S. Monoamine oxidase: isoforms and inhibitors in Parkinson’s disease and depressive illness. Br. J. Pharmacol., 2006, 147(Suppl.1), S287-S296.
70. Fernandez, H.H.; Chen, J.J. Monoamine oxidase-B inhibition in the treatment of Parkinson’s disease. Pharmacotherapy, 2007, 27(12), 174S-185S.
71. Knoll, J.; Ecseri, Z.; Kelemen, K.; Nievel, J.; Knoll, B. Phenylisopropylmethylpropinylamine (E-250), a new spectrum psychic energizer. Arch. Int. Pharmacodyn. Ther., 1965, 155, 154-164.
72. Stocchi, F.; Vacca, L.; Grassini P, De Pandis, M.F.; Battaglia, G.; Cattaneo, C.; Fariello, R.G. Symptom relief in Parkinson disease by safinamide: Biochemical and clinical evidence of efficacy beyond MAO-B inhibition. Neurology, 2006, 67(7 Suppl 2), S24-S29.
73. Henriot, S.; Kuhn, C.; Kettler, R.; Da Prada, M. Lazabemide (Ro 19-6327), a reversible and highly sensitive MAO-B inhibitor: Preclinical and clinical findings. J. Neural. Transm. Suppl., 1994, 41, 321-325.
74. Carradori, S.; Petzer, J.P. Novel monoamine oxidase inhibitors: a patent review (2012-2014). Exp. Opin. Ther. Patents, 2015, 25, 91-110.
75. Mathew, B.; Suresh, J.; Anbazhagan, S.; Mathew, G.E. Pyrazoline: A promising scaffold for the inhibition of Monoamine oxidase. Cent. Nerv. Syst. Agents Med. Chem., 2013, 13, 195-206.
76. Chimenti F.; Secci, D.; Bolasco, A.; Chimenti, P.; Bizzarri, B.; Granese, A.; Carradori, S.; Yáñez, M.; Orallo, F.; Ortuso, F.; Alcaro, S. Synthesis, molecular modeling, and selective inhibitory activity against human monoamine oxidases of 3-carboxamido-7-substituted coumarins. J. Med. Chem., 2009, 52, 1935-1942.
77. Chirkova, Z.V.; Kabanova, M.V.; Filimonov, S.I.; Abramov, I.G.; Petzer, A.; Petzer, J.P.; Firgang, S.I.; Suponitsky, K.Y. Inhibition of monoamine oxidase by indole-5,6-dicarbonitrile derivatives. Biorg. Med. Chem. Lett., 2015, 25, 1206-1211.
78. Carradori, S.; D’ Ascenzio, M.; Chimenti, P.; Secci, D.; Bolasco, A. Selective MAO-B inhibitors: A lesson from natural products. Mol. Divers., 2014, 18, 219-243.